Gilead Sciences Inc
NASDAQ: GILD
$89.14
-$1.49 (-1.6%)
Closing Price on January 8, 2025
GILD Articles
While not suited for conservative income investors, these two top biotech stocks could have huge total return potential and offer investors with a touch more risk tolerance some very tempting entry...
Published:
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including Amazon.com, Edwards Lifesciences, Gilead Sciences, Mastercard and Pinterest.
Published:
These four Jefferies stock picks in the health care space offer outstanding upside potential for investors long term and look like very solid ideas for the rest of 2021, especially with an overbought...
Published:
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Amazon, CME, Gilead Sciences and Twitter.
Published:
24/7 Wall St. looks at some big analyst calls that we have seen so far on Thursday, including Airbnb, Amazon, Fisker, Peloton, Uber and more.
Published:
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Booking, Expedia, FuelCell, Plug Power, Roku and more.
Published:
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Published:
Tuesday's top analyst upgrades and downgrades included Airbnb, American Express, Arch Capital, Carlyle, Darden Restaurants, Facebook, Eli Lilly and Nio.
Published:
As earnings season begins, Lululemon Athletica and other companies are updating guidance for the quarter just ended and for the 2020 fiscal year.
Published:
Although the markets may be falling, 24/7 Wall St. is taking a look at some big analyst calls that we have seen so far on Monday.
Published:
Thursday's top analyst upgrades and downgrades included AT&T, Boeing, ConocoPhillips, Gilead Sciences, Illumina, Lam Research, Raytheon Technologies and Yum Brands.
Published:
Galapagos was crushed on Wednesday after the firm, in conjunction with Gilead, announced a new commercialization and development agreement for their Rheumatoid Arthritis (RA) treatment.
Published:
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.